Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma.

Fennell DA, C Steele JP, Shamash J, Sheaff MT, Evans MT, Goonewardene TI, Nystrom ML, Gower NH, Rudd RM.

Lung Cancer. 2005 Feb;47(2):277-81.

PMID:
15639727
2.

Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.

Zucali PA, Ceresoli GL, Garassino I, De Vincenzo F, Cavina R, Campagnoli E, Cappuzzo F, Salamina S, Soto Parra HJ, Santoro A.

Cancer. 2008 Apr 1;112(7):1555-61. doi: 10.1002/cncr.23337.

3.

The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.

Stebbing J, Powles T, McPherson K, Shamash J, Wells P, Sheaff MT, Slater S, Rudd RM, Fennell D, Steele JP.

Lung Cancer. 2009 Jan;63(1):94-7. doi: 10.1016/j.lungcan.2008.04.001. Epub 2008 May 16.

PMID:
18486273
4.

A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma.

Kovac V, Zwitter M, Rajer M, Marin A, Debeljak A, Smrdel U, Vrankar M.

Anticancer Drugs. 2012 Feb;23(2):230-8. doi: 10.1097/CAD.0b013e32834d7a1c.

PMID:
22027538
5.

Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients.

Porta C, Zimatore M, Bonomi L, Imarisio I, Paglino C, Sartore-Bianchi A, Mutti L.

Lung Cancer. 2005 Jun;48(3):429-34. Epub 2005 Jan 24.

PMID:
15893013
6.

Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC.

Lena MD, Ramlau R, Hansen O, Lorusso V, Wagner L, Barni S, Cristovao MM, Huber R, Alberola V, Mitrovic M, Colin C, Gasmi J.

Lung Cancer. 2005 Apr;48(1):129-35. Epub 2004 Dec 21.

PMID:
15777980
7.

Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.

Zucali PA, Perrino M, Lorenzi E, Ceresoli GL, De Vincenzo F, Simonelli M, Gianoncelli L, De Sanctis R, Giordano L, Santoro A.

Lung Cancer. 2014 Jun;84(3):265-70. doi: 10.1016/j.lungcan.2013.11.011. Epub 2013 Nov 20.

PMID:
24321581
8.

Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant pleural mesothelioma. A multicenter Italian Phase II Study (SITMP1).

Pinto C, Marino A, De Pangher Manzini V, Benedetti G, Galetta D, Mazzanti P, Del Conte G, dell'Amore D, Piana E, Giaquinta S, Lopez M, Martoni A.

Lung Cancer. 2006 May;52(2):199-206. Epub 2006 Mar 20.

PMID:
16542747
9.

Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.

Guadagni S, Clementi M, Valenti M, Fiorentini G, Cantore M, Kanavos E, Amicucci G.

In Vivo. 2006 Nov-Dec;20(6A):715-8.

10.

Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma.

Sørensen JB, Frank H, Palshof T.

Br J Cancer. 2008 Jul 8;99(1):44-50. doi: 10.1038/sj.bjc.6604421. Epub 2008 Jun 10.

11.

A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma.

Zimling ZG, Sørensen JB, Gerds TA, Bech C, Andersen CB, Santoni-Rugiu E.

Cancer Chemother Pharmacol. 2012 Nov;70(5):743-54. doi: 10.1007/s00280-012-1965-0. Epub 2012 Sep 8.

PMID:
22960937
12.

Phase II study of vinflunine in malignant pleural mesothelioma.

Talbot DC, Margery J, Dabouis G, Dark G, Taylor H, Boussemart H, Cadic V, Pinel MC, Rivière A, Ollivier L, Ruffié P.

J Clin Oncol. 2007 Oct 20;25(30):4751-6.

PMID:
17947722
13.

Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study.

Castagneto B, Zai S, Dongiovanni D, Muzio A, Bretti S, Numico G, Botta M, Sinaccio G.

Am J Clin Oncol. 2005 Jun;28(3):223-6. Erratum in: Am J Clin Oncol. 2005 Oct;28(5):444. Sinaccio, G [added].

PMID:
15923792
14.

Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study.

Katirtzoglou N, Gkiozos I, Makrilia N, Tsaroucha E, Rapti A, Stratakos G, Fountzilas G, Syrigos KN.

Clin Lung Cancer. 2010 Jan;11(1):30-5. doi: 10.3816/CLC.2010.n.005.

PMID:
20085865
15.

Triplet chemotherapy with cisplatin, gemcitabine and vinorelbine for malignant pleural mesothelioma.

Maruyama R, Shoji F, Okamoto T, Miyamoto T, Miyake T, Nakamura T, Ikeda J, Aoki Y, Wataya H, Asoh H, Ichinose Y.

Jpn J Clin Oncol. 2005 Aug;35(8):433-8. Epub 2005 Jul 8.

PMID:
16006571
16.

Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.

Zauderer MG, Kass SL, Woo K, Sima CS, Ginsberg MS, Krug LM.

Lung Cancer. 2014 Jun;84(3):271-4. doi: 10.1016/j.lungcan.2014.03.006. Epub 2014 Mar 14.

17.

Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience.

Mir O, Alexandre J, Ropert S, Montheil V, Martin I, Durand JP, Goldwasser F.

Anticancer Drugs. 2009 Feb;20(2):105-8. doi: 10.1097/CAD.0b013e32831cdb51.

PMID:
19209026
18.

Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.

Jackman DM, Kindler HL, Yeap BY, Fidias P, Salgia R, Lucca J, Morse LK, Ostler PA, Johnson BE, Jänne PA.

Cancer. 2008 Aug 15;113(4):808-14. doi: 10.1002/cncr.23617.

19.

A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma.

Berghmans T, Lafitte JJ, Paesmans M, Stach B, Berchier MC, Wackenier P, Lecomte J, Collon T, Mommen P, Sculier JP; European Lung Cancer Working Party (ELCWP).

Lung Cancer. 2005 Oct;50(1):75-82.

PMID:
16005104
20.

Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force.

Pennucci MC, Ardizzoni A, Pronzato P, Fioretti M, Lanfranco C, Verna A, Giorgi G, Vigani A, Frola C, Rosso R.

Cancer. 1997 May 15;79(10):1897-902.

PMID:
9149015

Supplemental Content

Support Center